BLPH

Bellerophon Therapeutics, Inc. (BLPH) | Rumor.io

Bellerophon Therapeutics

BLPH

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about BLPH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Oct 16

Bellerophon Therapeutics, Inc. ($BLPH) traded 468% above average volume.
The stock is down -41.46% and some investors are considering it "dead".
There are questions about the stock's status, including why it's not trading and whether it will be tradeable in the future.

Generated by AI

Sentiment

Of the messages about BLPH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +14.29
Bearish	—	—	—	0% -14.29

Bullish· Jun 6

$BLPH has a strong cash position with $15M on hand, which could lead to a catalyst for price growth.
The company has a low float, with as few as 10 million outstanding shares, making it potentially volatile and attractive to investors.
$BLPH has seen significant buying activity, with over 3.39M shares traded and many of those being buys, indicating a strong potential for price growth.

Bearish· Jun 5

Bellerophon Therapeutics' ($BLPH) stock has dropped 82% due to its biotech nature, making it a high-risk investment.
The company's Phase 3 REBUILD clinical trial did not meet its primary endpoint, leading to a sharp drop in the stock price.
The failed trial and lack of a clear path forward for the company's lead candidate drug may result in a significant rebound, but investors should be cautious and only invest what they can afford to lose.

Generated by AI

Topics

Of the messages about BLPH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	35.71%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	64.29%

Announcements· Mar 6

Bellerophon Therapeutics, Inc. ($BLPH) announced a $5 million registered direct offering.
The offering was issued through a press release on March 6, 2023, at 8:30 AM EST.
Bellerophon Therapeutics entered into a subscription agreement with an institutional investor on March 3, 2023, for a material definitive agreement.

Technical Analysis· Dec 17

$BLPH formed a classic pre-market double top, but lacked range, making it not worth trading.
The stock has a double bottom pattern at $3 and a potential move from there, with a triple top at $3.04 that needs to be broken for a power hour run.
A bullish cross on the 1-hour chart and an ascending triangle on the 5-minute chart suggest a potential continuation, with a break above $3.20 needed for further upside.

Generated by AI

Community

Of the messages about BLPH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	26.32%
Newcomers	—	—	—	73.68%

Regulars· Jun 5

Bellerophon Therapeutics' Phase 3 REBUILD clinical trial for INOpulse in fibrotic interstitial lung disease did not meet its primary endpoint.
The trial's failure led to a 73.2% decline in Bellerophon Therapeutics' stock price.
Bellerophon Therapeutics' drug-device failed in another Phase 3 trial, causing the company's stock to implode.

Newcomers· Oct 13

Bellerophon Therapeutics' book value per share is estimated to be over $0.40, with the company potentially distributing this value to shareholders after debt and liabilities are settled.
The company's founders, Tang and Preceptive, have not sold their shares, suggesting they may be expecting a price north of $0.40 per share.
Bellerophon Therapeutics is set to be delisted and will hold a special meeting for dissolution and liquidation of assets, with approximately $1.28 per share in cash available to shareholders.

Generated by AI

Also Discussed

Investors talking about BLPH also mention

#	Name	Attention
1	Xtant Medical Holdings Inc.XTNT	0%0
2	Pulmatrix Inc.PULM	0%0
3	AB Corporate Bond ETFEYEG	0%0
4	Aurinia Pharmaceuticals IncAUPH	0.01%+0.01
5	Can-Fite BioPharma Ltd. ADRCANF	0%0
6	Cellectar Biosciences, Inc.CLRB	0%new
7	MRNS - Marinus Pharmaceuticals, Inc.	——
8	Euroseas Ltd.ESEA	0%0
9	APTO - Aptose Biosciences Inc.	——
10	EVOK - Evoke Pharma, Inc.	——